Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia - PubMed
5 hours ago
- #metastatic breast cancer
- #sacituzumab govitecan
- #safety analysis
- Sacituzumab govitecan (SG) improves survival in metastatic breast cancer (mBC) patients.
- Pooled safety analysis included 969 patients from North America/Europe (NA/EU) and Asia.
- Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 74% (NA/EU) and 78% (Asia) of patients.
- Low rates of TEAEs led to treatment discontinuation (5% NA/EU, 4% Asia) or death (1% NA/EU, 3% Asia).
- Common TEAEs: neutropenia, nausea, diarrhea (NA/EU); neutropenia, anemia, leukopenia (Asia).
- Safety profile was manageable and consistent across regions, supporting SG's use in mBC.